Lab USA, INC.

Lab USA, INC. was paid $4.51M by Medicaid between Jan 2018 and Apr 2024, across 65 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 48% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Massachusetts

Rank by total paid#12 of 63

Median peer was paid$473K

This provider vs. median9.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	60,290	$1.11M
2019	44,118	$1.16M
2020	21,485	$545K
2021	47,971	$917K
2022	24,118	$687K
2023	1,706	$83K
2024incomplete	194	$3K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	48%	42,412	25,183	$2.16M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	23%	25,645	10,802	$1.02M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	7.4%	4,719	3,680	$335K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	3.5%	2,050	1,047	$156K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	2.2%	4,646	3,603	$97K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.6%	3,634	3,478	$74K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.6%	3,632	3,478	$74K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.4%	3,909	3,777	$63K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	1.3%	13,369	12,802	$59K
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	1.2%	405	167	$54K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	2,102	1,453	$44K
84443	Thyroid stimulating hormone (TSH)	<1%	5,023	4,856	$42K

53 more codes

80061	Lipid panel	<1%	10,210	$39K
80053	Comprehensive metabolic panel	<1%	10,498	$33K
82607		<1%	3,477	$29K
86003		<1%	224	$23K
83036	Hemoglobin; glycosylated (A1C)	<1%	4,827	$22K
83013		<1%	694	$18K
ATP14		<1%	1,836	$13K
80050	General health panel	<1%	963	$12K
ATP18		<1%	1,594	$10K
80074		<1%	309	$10K
83550		<1%	1,775	$9K
84439		<1%	1,695	$9K
82746		<1%	1,034	$9K
82728		<1%	1,131	$9K
83540		<1%	2,110	$8K
84481		<1%	689	$7K
ATP17		<1%	1,386	$7K
87086	Culture, bacterial; quantitative colony count, urine	<1%	1,438	$7K
80048	Basic metabolic panel (calcium, ionized)	<1%	2,971	$6K
84153		<1%	566	$6K
86677		<1%	807	$6K
81003		<1%	4,577	$5K
86592		<1%	2,264	$5K
36415	Collection of venous blood by venipuncture	<1%	17,626	$5K
86703		<1%	609	$5K
86803		<1%	647	$4K
83735		<1%	1,498	$4K
80076		<1%	1,854	$3K
ATP15		<1%	430	$3K
82977		<1%	2,116	$3K
83014		<1%	734	$2K
ATP08		<1%	383	$2K
82550		<1%	907	$2K
87340		<1%	285	$1K
83655		<1%	117	$957.85
81001		<1%	376	$894.73
ATP19		<1%	78	$798.70
84480		<1%	516	$685.74
86430		<1%	166	$673.17
84550		<1%	362	$563.60
85651		<1%	191	$472.14
81015		<1%	1,872	$415.84
82947		<1%	136	$348.45
ATP16		<1%	32	$315.81
87070		<1%	19	$159.84
84703		<1%	15	$90.96
80051		<1%	28	$73.82
ATP04		<1%	27	$72.40
82565		<1%	69	$51.28
84100		<1%	123	$36.08
ATP03		<1%	14	$34.25
84520		<1%	14	$17.42
84075		<1%	17	$5.34

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialAFREEDI, MOHAMMAD (CEO AND PRESIDENT)